Fig. 2

Cumulative incidence of therapeutic failure or HAP-VAP relapse among the IPTW pseudo-cohort treated by conventional (control group; full line) or increased (treatment group; dotted line) β-lactam dosing regimens. Data adjusted on propensity score, SAPS 2 and PaO2/FiO2 ratio